Don't click any links by The Street. Let AF flounder for his .10 clicks!!
Somebody had information.
I have made it a habit to not click or open any emails from Motley Fools, SA or Street.
SNY floated MNKD a loan as part of the agreement. Totally different than the milesone payments. The loan would have to be paid back over the 10 years. While the milestone isn't recognized as revenue, I have never heard that it couldn't be used as operating cash.
Wicked game this stock market is!
Not a conspiracy. Most likely fact. The Israelis have the option to buy their shared on the open market should they choose. Why wouldn't they if they can get a lower share price? It's not like the Israelis aren't working in NYC! They are all the same bunch.
Kev. You know as well as everyone else that the could never say that outright. That would trigger lawsuits that would never end if it were to happen. You have really been all over the place the last couple of days. I generally like your content but wondering these days.
Sanofi isn't going anywhere. They are doing exactly what has been communicated so far. My favorite is "expanding" number of physician targets. Thus the flat script number each week. They are focusing on a set of physicians and establishing baselines.
U.S. Launch in Feb 2015
● Time needed for Afrezza® to demonstrate its potential
● Gradual market access
● FDA requirements for starting patients on Afrezza®
● Novel mode of administration and innovative nature of the
● DTC advertising campaign and expanded number of
physician targets for sales force
● Commercial focus on ~1.1m uncontrolled basal
insulin intensification patients
Their website states after each meeting the Agency publishes a table highlighting decisions taken. Not sure of the timelines, but if Afrezza was on the books we should know shortly.
Some day they will all be gone matese. I can't begin to understand the idiocy and time put out on this message board. Just can't fathom the purpose.
Nice work. I love how shorts are screaming "it doesn't say Afrezza anywhere!" Well the same people fail to mention it doesn't say the name of any drug "anywhere." It's a huge sales conference with small regional breakout sessions and sales leadership meetings. Logic dictates it's to do with Toujeo and/or Afrezza.
Or they are still deciding which tier to slot both of the into. My understanding is that Sanofi is working on formulary issues with insurers currently. I am curious if Afrezza was ever on the list previously. Or Toujeo for that matter.
I am sure the list is amended all the time and someone is just taking this as an opportunity to highlight it not being shown.